Granules India Ltd (BSE: 532482) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹20,836 Cr, it ranks #361 by market cap among the 6,197 Indian listed companies on FinBizNet, and #16 of 86 in Medicinal Chemicals and Botanical Products. At ₹814.00 (as of 16 Nov 2026), the share price is 11.9% below its 52-week high of ₹923.65 and 53.6% above its 52-week low of ₹529.85. The share price is up 47.3% over one year and down 5.2% over three months.
| Current Price | ₹814.00 |
|---|---|
| Market Cap | ₹20,836 Cr |
| BSE Code | 532482 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 34.3 |
| Return on Equity | 13.52% |
| Return on Assets | 7.98% |
| 52-Week Range | ₹529.85 – ₹923.65 |
| 1-Year Price Change | +47.3% |
| 3-Month Price Change | -5.2% |
| Beta (1Y) | 0.35 |
| Dividend Yield | 0.21% |
| Headquarters | Hyderabad, Telangana |
| Website | www.granulesindia.com |
| Revenue | ₹1,560 Cr |
|---|---|
| Net Profit | ₹182 Cr |
| Net Margin | 11.7% |
| EPS (Basic) | ₹7.22 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Granules India Ltd reported revenue of ₹1,560 Cr in Q2 FY27, up 20.3% from ₹1,297 Cr in Q2 FY26 and up 5.6% from ₹1,477 Cr in Q1 FY27. It posted a net profit of ₹182 Cr for the quarter, against a net profit of ₹131 Cr in Q2 FY26 (up 39.2%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,197 Cr (Q4 FY25) to ₹1,560 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹1,560 Cr | ₹182 Cr | 11.7% |
| Q1 FY27 | ₹1,477 Cr | ₹180 Cr | 12.2% |
| Q4 FY26 | ₹1,471 Cr | ₹202 Cr | 13.7% |
| Q3 FY26 | ₹1,388 Cr | ₹150 Cr | 10.8% |
| Q2 FY26 | ₹1,297 Cr | ₹131 Cr | 10.1% |
| Q1 FY26 | ₹1,210 Cr | ₹113 Cr | 9.3% |
| Q4 FY25 | ₹1,197 Cr | ₹152 Cr | 12.7% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 37.39% of Granules India Ltd's shares as of Sept 2026, against 38.82% in Dec 2025 (−1.43 percentage points). Delivery averaged 47.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating
1. Manufacture of Pharmaceuticals-This segment offers pharmaceutical products, including ingredients and intermediaries. 2. Active Pharmaceutical Ingredients (API's)-This segment engages in the production and sale of active pharmaceutical ingredients, including metformin, methocarbamol, guaifenesin, phenazopyridine, and paracetamol, or acetaminophen. 3. Pharmaceutical Formulation Intermediates (PFI's)-This segment engages in the production and sale of pharmaceutical formulation intermediates.
1. Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Granules India Ltd | ₹20,836 Cr | 34.3 | 13.52% | ₹1,560 Cr | +47.3% |
Listed by market capitalisation. Ratios are shown for context only.
Granules India Ltd is trading at ₹814.00, with a market capitalisation of ₹20,836 Cr.
Granules India Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Granules India Ltd has a P/E of 34.3 and a return on equity of 13.52%.
Granules India Ltd is listed on the BSE under the scrip code 532482.
Granules India Ltd's share price is up 47.3% over one year and down 5.2% over three months. Its 52-week range is ₹529.85 to ₹923.65.
In Q2 FY27, Granules India Ltd reported revenue of ₹1,560 Cr and net profit of ₹182 Cr, with basic EPS of ₹7.22 (consolidated, parsed from the company's exchange filing).
Granules India Ltd reported revenue of ₹1,560 Cr in Q2 FY27, up 20.3% from ₹1,297 Cr in Q2 FY26 and up 5.6% from ₹1,477 Cr in Q1 FY27.
Promoters held 37.39% of Granules India Ltd's shares as of Sept 2026, against 38.82% in Dec 2025 (−1.43 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.